Abstract
Influenza-associated pulmonary aspergillosis (IAPA) is a feared complication in patients with influenza tracheobronchitis, especially those receiving corticosteroids. Herein, we established a novel IAPA mouse model with low-inoculum Aspergillus infection and compared outcomes in mice with and without cortisone acetate (CA) immunosuppression. CA was an independent predictor of increased morbidity/mortality in mice with IAPA. Early antifungal treatment with liposomal amphotericin B was pivotal to improve IAPA outcomes in CA-immunosuppressed mice, even after prior antiviral therapy with oseltamivir. In summary, our model recapitulates key clinical features of IAPA and provides a robust preclinical platform to study the pathogenesis and treatment of IAPA.
Original language | English (US) |
---|---|
Pages (from-to) | 901-906 |
Number of pages | 6 |
Journal | Journal of Infectious Diseases |
Volume | 227 |
Issue number | 7 |
DOIs | |
State | Published - Apr 1 2023 |
Keywords
- amphotericin B
- aspergillosis
- corticosteroids
- influenza
- mouse model
- oseltamivir
- pneumonia
ASJC Scopus subject areas
- Immunology and Allergy
- Infectious Diseases